Pharmacogenomic Testing: Delivering Precision Medicine

By reducing adverse drug responses, improving efficacy, and ensuring each patient gets the drug they are most likely to respond to, pharmacogenomics testing helps deliver the promise of precision medicine. In order to help empower the personalization of cancer treatment, we offer pharmacogenomic testing for doctors, hospitals, and cancer centers, as well as for biopharma and biotech companies engaged in oncology-focused clinical trials.

Below is a sample of the pharmacogenomic genotyping assays we offer for central nervous system (CNS) drugs. In addition to conventional pharmacogenomics tests, we are experienced in providing custom assay development and validation.

ABAT
ABCB1
ABCC2
AOX1
APOE
ATM
ATR
CHRFAM7A
CHRNA7
CRHR1
CYP2B6
CYP2C19
CYP2C8
CYP2D6
CYP3A4
CYP3A5
GABRR1
GABRR2
GRIP2
Intergenic between GABRR1 and GABRR2
NAT1
NAT2
NRG1
PM20D2
PON1
SLC36A1
SLC36A11
SLC36A13
SLC6A6
SLCO1B1
THEM186
UGT2B7